ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.936,82
0,08%
S&P 500
5.018,39
-0,34%
Dow Jones
37.903,29
0,23%
Euro vs US Dollar
1,06981
-0,18%
Bitcoin
57.777,19
-0,80%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Exelixis Inc (EXEL)

  7. Exelixis Inc (EXEL) News

EXEL Exelixis Inc

21,925
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 11:28:36
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Exelixis Inc EXEL NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 21,925 11:28:36
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
21,925
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
30.4.202422:05BWExelixis Announces First Quarter 2024 Financial Results and..
16.4.202422:05BWExelixis to Release First Quarter 2024 Financial Results on..
28.2.202400:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.2.202400:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.2.202400:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.2.202400:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.2.202400:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.2.202400:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202422:05BWExelixis to Webcast Fireside Chats as Part of Investor..
24.2.202400:33EDGAR2Form 144 - Report of proposed sale of securities
22.2.202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.2.202401:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.2.202415:19EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06.2.202422:49EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06.2.202422:28EDGAR2Form 8-K - Current report
06.2.202422:05BWExelixis Announces Fourth Quarter and Fiscal Year 2023..
01.2.202422:05BWExelixis to Webcast Fireside Chats as Part of Investor..
25.1.202414:00BWExelixis Announces Detailed Results of Phase 3 CONTACT-02..
23.1.202422:05BWExelixis to Release Fourth Quarter and Fiscal Year 2023..
22.1.202423:00BWOpdivo® (nivolumab) in Combination with CABOMETYX®..
18.1.202422:05BWEuropean Patent Office Rules in Favor of Exelixis on..
17.1.202402:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202402:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202402:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202402:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202402:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.1.202403:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.1.202403:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.1.202403:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
10.1.202403:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
08.1.202415:06EDGAR2Form 8-K - Current report
07.1.202422:00BWExelixis Announces Preliminary Fiscal Year 2023 Financial..
02.1.202422:05BWExelixis to Present at the 42nd Annual J.P. Morgan..
20.12.202322:20EDGAR2Form 8-K - Current report
15.12.202301:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.12.202301:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.12.202322:56EDGAR2Form 144 - Report of proposed sale of securities
13.12.202322:27EDGAR2Form 144 - Report of proposed sale of securities
12.12.202322:26EDGAR2Form 144 - Report of proposed sale of securities
07.12.202322:05BWExelixis 2023 R&D Day: Science & Strategy to be Webcast on..
05.12.202300:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.12.202314:02BWExelixis Announces Initiation of the STELLAR-305 Phase 2/3..
04.12.202314:00BWExelixis and Arcus Biosciences Announce Clinical Trial..
30.11.202322:10EDGAR2Form 144 - Report of proposed sale of securities
29.11.202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.11.202322:05BWExelixis to Present at the Piper Sandler 35th Annual..
21.11.202301:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.11.202315:00BWExelixis Announces Encouraging Results from Expansion Cohort..
09.11.202322:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.11.202321:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Kürzlich von Ihnen besucht

NASDAQ
EXEL
Exelixis
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten